# GAIA Biomedical Interface and Biosafety Spec v1.0
**Clinical Interface Boundaries, Biosecurity Controls, Oversight, and Safe Biomedical Intelligence**

*Compiled by: Societas AI Research Team*
*Date: March 14, 2026*
*Classification: P0 Critical - Biomedical Boundary and Safety Spec*

---

## Executive Summary

This specification defines how GAIA may interact with biomedical data, clinical interfaces, public-health intelligence, biological models, and biosafety-sensitive workflows.

This is **not** an authorization for unrestricted biomedical experimentation. It is a boundary and control document.

The specification establishes four simultaneous goals:

1. allow safe biomedical sensing, data integration, and decision support;
2. prevent unsafe or noncompliant biological design or laboratory use;
3. preserve human clinical authority and biosafety governance;
4. make all biomedical intelligence auditable, bounded, and revocable.

**Core position:**
GAIA MAY support biomedical understanding, triage support, biosurveillance, and research coordination only inside explicit authority, privacy, and biosafety constraints. GAIA SHALL NOT become an unrestricted system for pathogen design, unsupervised wet-lab execution, or opaque clinical decision substitution.

---

## 1. Scope

### 1.1 In Scope

- health and biomedical data interfaces;
- patient-safe decision support patterns;
- device, sensor, and record integration;
- biosurveillance and population-health analytics;
- biomedical digital twin primitives;
- institutional biosafety and biosecurity controls;
- oversight of in silico biological model use.

### 1.2 Out of Scope

- procedural wet-lab protocols;
- autonomous clinical practice;
- autonomous prescribing or surgery;
- pathogen enhancement support;
- design assistance for harmful biological agents or toxins;
- bypass of institutional review, biosafety, or legal obligations.

---

## 2. Normative Principles

1. **Clinical judgment remains primary**
2. **Minimum necessary data access**
3. **Biomedical actuation is higher risk than biomedical observation**
4. **In silico capability does not remove biosafety obligations**
5. **Human, animal, plant, and ecosystem health are linked**
6. **Every biomedical model must have an operating envelope**
7. **Biosecurity review applies to digital as well as physical workflows**
8. **High-risk biological content must default to refusal, escalation, or containment**

---

## 3. Biomedical Capability Classes

| Class | Meaning |
|---|---|
| B0 | general biomedical knowledge and literature synthesis |
| B1 | non-patient-specific analytics and biosurveillance |
| B2 | patient- or specimen-adjacent decision support under supervision |
| B3 | workflow influence over clinical or laboratory operations |
| B4 | prohibited or separately governed high-risk biological capability |

All new biomedical features default to **B0** until classified.

---

## 4. Biomedical Interface Domains

### 4.1 Human Health Interfaces

- EHR / EMR interoperability
- laboratory result ingestion
- physiologic sensor streams
- imaging metadata linkage
- care pathway support
- public-health reporting interfaces

### 4.2 Biological Research Interfaces

- omics data integration
- biobank metadata
- environmental and host-pathogen surveillance
- epidemiological modeling
- research knowledge graph integration

### 4.3 Device and Sensor Interfaces

- wearable devices
- bedside monitors
- environmental biosensors
- lab instrument metadata
- regulated medical device telemetry where authorized

---

## 5. Clinical Decision Support Boundary

### 5.1 CDS Rule

GAIA MAY provide clinical decision support only when:

- intended user and patient context are defined,
- required inputs are explicit,
- output is explainable enough for qualified independent review,
- operating envelope and limitations are disclosed,
- uncertainty is visible,
- logs are preserved.

### 5.2 Non-Substitution Rule

GAIA SHALL NOT present outputs in a way that induces blind reliance by clinicians when independent review is expected.

### 5.3 High-Risk Escalation Rule

Outputs indicating severe deterioration, urgent triage, sepsis-like risk, overdose risk, violence/self-harm risk, or other high-consequence clinical states SHALL route through predefined escalation logic and institutional policy.

---

## 6. Biosafety and Biosecurity Controls

### 6.1 Risk Categories

GAIA SHALL treat the following as requiring elevated review:

- work involving dangerous pathogens or toxins,
- high-risk gain-of-function or enhanced transmissibility concerns,
- dual-use biological design,
- model outputs that could materially enable harmful biological manipulation,
- unsafe laboratory workflow automation.

### 6.2 Digital Biosecurity Rule

Any in silico capability that could materially enable harmful biological design SHALL be subject to institutional review, logging, access control, and content restriction.

### 6.3 Prohibited Assistance

GAIA SHALL refuse or route away from requests that seek:

- construction, enhancement, or optimization of harmful biological agents;
- experimental designs intended to increase pathogenicity, transmissibility, immune escape, or environmental persistence;
- operational guidance that bypasses biosafety oversight.

---

## 7. Oversight Architecture

### 7.1 Required Governance Bodies

Biomedical deployments SHALL identify:

- product owner,
- privacy officer,
- institutional clinical authority,
- biosafety / biosecurity authority,
- security authority,
- model validation lead.

### 7.2 Review Triggers

Review is mandatory for:

- any B2+ deployment,
- any use of protected health or personally identifiable biomedical data,
- any integration with clinical workflow,
- any in silico biological modeling with potential dual-use implications,
- any change to intended use.

---

## 8. Data Governance

### 8.1 Data Classes

| Class | Example |
|---|---|
| PHI / personal clinical data | records, identifiers, visits |
| de-identified clinical data | cohort analytics |
| biological specimen metadata | sample, collection, storage status |
| omics and sequence data | genomic / transcriptomic / proteomic outputs |
| biosurveillance data | wastewater, zoonotic, environmental signals |
| literature / knowledge artifacts | publications, guidelines, formularies |

### 8.2 Required Controls

- lawful authority and purpose binding
- least-privilege access
- encryption in transit and at rest
- auditable access logs
- retention controls
- de-identification where possible
- red-team review for re-identification risk in sensitive datasets

---

## 9. Biomedical Model Governance

Every biomedical model SHALL ship with:

- intended use statement,
- excluded uses,
- training data summary,
- calibration and validation evidence,
- subgroup limitations if known,
- abstention conditions,
- human review expectation,
- change log,
- rollback path.

Example model card fragment:

```yaml
biomedical_model_card:
  model_id: gaia:model/clinical-deterioration-risk-v1
  intended_use: "supplemental inpatient deterioration screening"
  excluded_uses:
    - autonomous triage
    - diagnosis without clinician review
    - pediatric use unless separately validated
  input_requirements:
    - vital_signs_freshness_lt_minutes: 15
    - lab_panel_age_lt_hours: 12
  abstain_conditions:
    - missing_respiratory_rate
    - conflicting_identity_records
    - out_of_distribution_signal
```

---

## 10. Laboratory and Institutional Boundary Model

### 10.1 Separation Rule

GAIA SHALL distinguish among:

- **knowledge support**,
- **administrative workflow support**,
- **instrument data ingestion**,
- **laboratory planning support**,
- **physical experimental execution**.

Each boundary crossing raises risk class.

### 10.2 Wet-Lab Control Rule

Any connection from GAIA to equipment that can alter biological materials SHALL be treated as safety-critical and requires separate authorization, hard control envelopes, and institutional oversight.

---

## 11. Public Health and Biosurveillance

GAIA MAY support:

- epidemiological signal aggregation,
- wastewater and sentinel surveillance integration,
- outbreak situational awareness,
- anomaly detection,
- resource and logistics planning.

GAIA SHALL distinguish clearly between:

- signal detection,
- inference,
- diagnosis,
- declaration of public-health emergency.

Only the first two are within default system scope.

---

## 12. One Health Integration

Biomedical intelligence SHALL be capable of linking:

- human health signals,
- animal health signals,
- plant health signals,
- environmental conditions,
- water and food safety,
- antimicrobial resistance indicators.

This linkage is necessary because public health, agriculture, and ecosystem risk often share causal infrastructure.

---

## 13. Verification and Validation

Required test families for B2+ systems:

- identity resolution and record linkage tests
- explanation visibility tests
- subgroup performance analysis
- abstention-path tests
- stale-data tests
- clinical workflow simulation
- biosafety access-control tests
- incident logging and replay tests

---

## 14. Incident and Escalation Policy

A biomedical incident includes:

- unsafe or misleading clinical recommendation,
- privacy breach,
- access to restricted biological content,
- unreviewed change in intended use,
- unsafe coupling to a laboratory or device workflow,
- biosurveillance false escalation caused by governance failure.

All incidents SHALL trigger containment, evidence preservation, and formal review.

---

## 15. Research Grounding

This specification is aligned with current WHO biosafety guidance, NIH / OSTP oversight patterns for dual-use and biological research risk, and current FDA guidance for medical device cybersecurity and clinical decision support boundaries. The document intentionally remains at the policy and architecture level rather than providing actionable biological procedures.

---

## 16. Conclusion

GAIA can contribute meaningfully to medicine and biosurveillance only if it remains bounded by human authority, privacy discipline, and biosafety logic. Without those controls, biomedical intelligence becomes unacceptable risk.
